Tigecycline is a last-resort antibiotic that is used to treat severe infections caused by extensively drug-resistant bacteria. However, the efficacy and safety data for tigecycline in infectious patients are lacking. The aim of this study is to assess the efficacy and safety of tigecycline in infectious patients using pharmacokinetics and omics.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Adverse events
Timeframe: Through study completion, an average of 15 days
Pharmacokinetics of tigecycline
Timeframe: Through study completion, an average of 3 days
Rate constant for tigecycline distribution
Timeframe: Through study completion, an average of 3 days
The ratio of area under the concentration-time curve (AUC) to minimum inhibitory concentration (MIC).
Timeframe: Through study completion, an average of 3 days